Company facts
Early-stage
- Founded
- 2024
- Employees
- 2
- Headquarters
- United States
About
We are developing cancer therapeutics using small molecules that inhibit immune suppression. Our drugs engage the immune system to aggressively fight tumors. Our therapeutic portfolio addresses a range of solid tumors, starting with mesothelioma.